Femasys (NASDAQ:FEMY) Price Target Lowered to $8.00 at Chardan Capital

Femasys (NASDAQ:FEMY) had its target price lowered by stock analysts at Chardan Capital from $10.00 to $8.00 in a research note issued on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock.

Separately, HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Femasys in a report on Tuesday.

Femasys Price Performance

NASDAQ:FEMY remained flat at $1.03 during trading hours on Wednesday. The company’s stock had a trading volume of 308,506 shares, compared to its average volume of 333,667. The company has a debt-to-equity ratio of 0.43, a quick ratio of 5.93 and a current ratio of 6.47. The firm’s fifty day simple moving average is $1.16 and its 200-day simple moving average is $1.15. The stock has a market capitalization of $22.90 million, a PE ratio of -1.27 and a beta of -2.83. Femasys has a 52-week low of $0.73 and a 52-week high of $2.40.

Femasys (NASDAQ:FEMY) last announced its earnings results on Tuesday, November 12th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.04). Femasys had a negative net margin of 1,435.77% and a negative return on equity of 120.13%. The firm had revenue of $0.55 million during the quarter, compared to analyst estimates of $0.40 million. As a group, research analysts predict that Femasys will post -0.79 earnings per share for the current year.

Hedge Funds Weigh In On Femasys

A hedge fund recently raised its stake in Femasys stock. CM Management LLC lifted its position in shares of Femasys Inc. (NASDAQ:FEMY) by 6.3% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 425,000 shares of the company’s stock after buying an additional 25,000 shares during the period. CM Management LLC owned approximately 1.91% of Femasys worth $484,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 65.27% of the company’s stock.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.